Research
Meet Winnie, the 11-Year-Old Author Helping Kids Face Surgery
Winnie is an 11-year-old living with spinal muscular atrophy (SMA) who loves musicals, drawing, and playing sports with her brothers. After her recent surgery, she […]
Adults with SMA Share Their Unmet Needs and Independence Barriers in Washington D.C.
This week, the unmet health and everyday living needs of adults with spinal muscular atrophy (SMA) took center stage in Washington, DC, in an event […]
The 2026 Annual SMA Research & Clinical Care Meeting Summaries Are Here!
In June, SMA researchers and clinicians from around the world gathered in Orlando for the 30th Annual SMA Research & Clinical Care Meeting – to […]
FDA Grants Breakthrough Therapy Designation to Biogen’s Salanersen for Spinal Muscular Atrophy
Biogen recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to salanersen, an investigational therapy being studied for the […]
Cure SMA Releases Updated Combination Therapy Booklet and New Video on Muscle-Directed Therapy
As more SMA treatments become available, people living with SMA, their families, and caregivers are asking new questions about how treatments work, whether using more […]
Cure SMA Shares Research Insights with Scientists and Clinicians at Spring 2026 Conferences
Cure SMA is pleased to announce the participation of our Research Department staff in the following conferences: 2026 Muscular Dystrophy Association (MDA) Virtual Clinical & […]
Cure SMA Releases the 2025 Annual State of SMA Report
Cure SMA is pleased to announce the publication of the 5th annual State of SMA report. Drawing on data collected by Cure SMA through 2025, […]
The 10th Annual Cure SMA Community Update Survey Is Now Available
Since 2017, 3,200 people have shared their experiences and unmet needs through the Cure SMA Community Update Survey. The Community Update Survey is an annual […]
Cure SMA Awards $150,000 Grant to Tetsuya Akiyama, MD, PhD, Stanford University School of Medicine
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]
Genentech Issues Community Letter Regarding Emugrobart
Today, Genentech announced the discontinuation of emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for spinal muscular atrophy (SMA). The […]